Lilly's arzoxifene meets Phase III endpoints

Eli Lilly (NYSE:LLY) said its arzoxifene was superior to Evista raloxifene in the double-blind, international Phase III NEXT trial to treat postmenopausal osteoporosis. Arzoxifene increased bone miner...